Bli medlem
Bli medlem

Du är här


Alligator Bioscience: Change in number of shares and votes in Alligator Bioscience AB (publ)

Press release, January 31, 2017

During December, the number of shares and votes in Alligator
Bioscience AB (publ) has increased due to that 700,000 warrants in
the warrant program 2014/2017 issued pursuant to the resolution by
the extraordinary shareholders' meeting on 5 November 2013 have been
excercised for subscription of 700,000 new shares. As of January 31,
2017, the number of shares and votes in Alligator Bioscience AB
amounts to 70,813,615.

About Alligator
Alligator is a research-based biotechnology company that develops
innovative immune activating antibody drugs for tumor-directed
immunotherapy. The Company is headquartered in Lund, Sweden, and had
35 employees per December 31, 2016. The Company is primarily active
in the early stages of drug development, from the idea stage to
clinical phase IIa studies, and Alligator's product portfolio
primarily consist of the product candidates ADC-1013, ATOR-1015 and
ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen
Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson
& Johnson, for further development and commercialization. The
company's shares are listed on Nasdaq Stockholm under the ticker
"ATORX". For more information, visit

For further information, please contact:
Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard)

Rein Piir, VP Investor Relations
Telephone: +46 708 53 72 92

The information in the press release is such that Alligator Bioscience
AB is required to disclose pursuant to the Swedish Financial
Instruments Trading Act. The information was submitted for
publication, through the agency of the contact persons set out above,
at 08.30 CET on January 31, 2017.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.